Answers are grounded in this paper and cite their sources.
Objective: The objectives are to identify the patient selection factors that indicates the patients has reasonable likelihood of success with an ultraradical local-regional treatment strategy. The treatments are described and the expected results of treatment presented. Background: Peritoneal mesothelioma is an unusual malignancy in that it has no known primary site and progression is limited to the surfaces of the abdomen and pelvis throughout its natural history. Methods: The patient- and disease-related variables and their impact on prognosis were presented. Also, treatment-related variables and their application to the patient with MPM were presented. Recommendations currently are for upfront treatment using cytoreductive surgery (CRS) with peritonectomy and visceral resections. At the completion of CRS, hyperthermic intraperitoneal chemotherapy (HIPEC) is administered. Then the intestines are reconstructed and the abdomen closed. EPIC with paclitaxel proceeds for the first five postoperative days. An intraperitoneal port must be placed prior to abdominal closure so that five cycles of normothermic intraperitoneal paclitaxel can be administered. Conclusions: Survival up to 70% at 10 years is possible in carefully selected patients treated by complete CRS, hyperthermic intraperitoneal chemotherapy (HIPEC), EPIC and NIPEC. Successful ultraradical local-regional treatment for this disease may be facilitated by a centralization of efforts.
No takes yet. Share an insight, caveat, or question.
Paul H. Sugarbaker (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: